Akebia Therapeutics, Inc. Uncategorized Contracts & Agreements
18 Contracts & Agreements
- Packaging Validation Transfer Agreement, dated April 20, 2023, by and between the Company and Otsuka Pharmaceutical Co. Ltd (Filed With SEC on August 28, 2023)
- Amendment No. 5 (Filed With SEC on May 8, 2023)
- Amended and Restated (Filed With SEC on May 8, 2023)
- Open Market Sale AgreementSM, dated April 7, 2022, by and between Akebia Therapeutics, Inc. and Jefferies LLC (Filed With SEC on April 7, 2022)
- First Amendment and (Filed With SEC on March 1, 2022)
- Royalty Interest Acquisition Agreement, dated February 25, 2021, by and between the Company and HealthCare Royalty Partners IV, L.P (Filed With SEC on May 10, 2021)
- Description of Registrants Securities (Filed With SEC on February 25, 2021)
- Offer Letter to David Spellman, dated as of June 13 (Filed With SEC on August 10, 2020)
- Description of Registrants Securities (Filed With SEC on March 12, 2020)
- Letter Agreement by and between Panion & BF Biotech, Inc., the Company and Keryx Biopharmaceuticals, Inc. dated October 24, 2018 (Filed With SEC on March 26, 2019)
- Offer Letter to Rita Jain, dated April 28, 2017 (Filed With SEC on March 12, 2018)
- Letter Agreement between Akebia Therapeutics, Inc. and Mitsubishi Tanabe Pharma Corporation, dated September 26, 2017 (Filed With SEC on November 8, 2017)
- CONFIDENTIAL (Filed With SEC on May 9, 2017)
- SEPARATIONAGREEMENT (Filed With SEC on February 14, 2014)
- CONSULTINGAGREEMENT (Filed With SEC on February 14, 2014)
- AMENDMENT NUMBER TWO TO THE SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (Filed With SEC on February 14, 2014)
- AMENDMENT NUMBER ONE TO SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (Filed With SEC on February 14, 2014)
- SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (Filed With SEC on February 14, 2014)
